Recurrent disability progression endpoints in multiple sclerosis clinical trials.

Alexandra BühlerMarcel WolbersFabian ModelQing WangShibeshih BelachewMarianna ManfriniJohannes LorscheiderLudwig KapposJan Beyersmann

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

Our results support the use of recurrent event data analysis, especially in progressive MS trials, to improve estimates of treatment effects, increase statistical power, and better capture the clinically meaningful long-term disability progression experience.

Keyphrases

multiple sclerosis
data analysis
clinical trial
white matter
randomized controlled trial
phase ii